Navigation Links
Boffins Identify Gene That can Protect Humans from Nephronopthisis

Researchers from the European Molecular Biology Laboratory (EMBL) and the University of Michigan have identified a gene that can protect humans from nephronopthisis (NPHP), a serious kidney disease .

NPHP is a disease that causes kidney degeneration during childhood and kidney failure requiring organ transplantation. The insights might help design effectual and non-invasive therapies.

The team has discovered that mutations in the gene GLIS2 can lead to nephronopthisis (NPHP) in both humans and mice.

Mathias Treier and his group at EMBL have paved way to develop innovative treatment for the disease by working on a mouse model.

"Our mice show striking similarities with NPHP patients. Very early on in their lives their kidney cells start to die and the mice develop all the characteristic disease symptoms. It is the first time that a mouse model reveals increased cell death as the mechanism underpinning kidney degeneration in NPHP. The genetic cause is a mutation in a gene called GLIS2," Nature Genetics quoted Mathias Treier, group leader at EMBL, as saying.

GLIS2 protects adult kidney against cell death by turning off genes that trigger cell death, and that are necessary for the organ development.

A change in the GLIS2 function sets off harmful genes leading to large numbers of kidney cells' death..

To see if GLIS2 has the same result on human, Friedhelm Hildebrandt and his team at the University of Michigan carried out a genetic screening of those having NPHP. They found that some patients carried mutations in the same GLIS2 gene as in the mouse model confirming that GLIS2 is a crucial player in NPHP also in humans.

"This is an excellent example of how combining basic research with clinical studies can help uncovering mechanisms of human disease," said Henriette Uhlenhaut who carried out the research in Treier's lab.

"The next step will be to translate the insights gained into new therapeutic approaches to develop alternatives to kidney transplantations. With GLIS2 we have already identified one promising candidate drug target and our mouse model will help us find many others," he added.

The study is available in the current online issue of Nature Genetics.


'"/>




Related medicine news :

1. Fizzy Logic For A Perfect Drink: Courtesy Boffins
2. Boffins Identify Fifth Gene Behind Joubert Syndrome
3. Boffins Find Link Between Common Sleep Disorder and Hypertension
4. Boffins Identify Molecule That Might Treat Food Allergy
5. Boffins a Step Closer to Solving Puzzle of Lou Gehrigs Disease
6. Boffins Identify Gene That Helps Regulates Body Weight
7. Boffins Link Atkins Diet With Bowel Cancer
8. Boffins Develop New Technique to Hunt Illness-causing Mutants in Non-gene DNA
9. Boffins Find Evidence for Novel Brain Cell Communication
10. Indian Boffins to Fight Wrinkles With Camels Milk
11. Laboratory Testing Can Identify Risk of Pre-Term Labor and Delivery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology: